EG 006
Alternative Names: EG006; VitorLatest Information Update: 16 Sep 2010
At a glance
- Originator Unknown
- Developer Ark Therapeutics
- Class Small molecules
- Mechanism of Action Angiotensin type 2 receptor antagonists; Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cachexia
Most Recent Events
- 09 Sep 2010 Discontinued - Phase-II/III for Cachexia in USA (PO)
- 09 Sep 2010 Discontinued - Phase-III for Cachexia in Europe (PO)
- 28 Jan 2010 Suspended - Phase-II/III for Cachexia in USA (PO)